Skip to content

Addiction: all studies

Page 180 of 855: studies 1,791 to 1,800 of 8,547, newest first. Back to the addiction overview

Research

Neurovascular Architecture Of The Brain As A Limit Of Biological Reproducibility: From The Connectome And Vasculome To The Problem Of Consciousness Identity

Zenodo (CERN European Organization for Nuclear Research) June 1, 2026 Юр'єв Віктор Єгорович Viktor Yuriev preprint

This article examines the human brain as an integrated neurovascular architecture in which neuronal, vascular, glial, and metabolic components form a unified functional system. Drawing on contemporary findings in neuroscience, the study analyzes mechanisms of neurovascular coupling, the role of the blood–brain barrier, the glymphatic system, and the energetic foundations of cognitive processes....

DOI: 10.5281/zenodo.20492819 (opens in new tab) Consciousness Neurovascular bundle Identity music Glymphatic system +9

The impact of ketamine on posttraumatic stress disorder (PTSD) symptomatology in trauma-exposed populations: a narrative review.

Journal of trauma and injury June 1, 2026 Minaal Ahmed Malik, Michele Halasa, Jack Chia et al.

Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, is widely used in trauma and emergency medicine for its rapid analgesic and sedative properties. While its efficacy in acute pain management is well established, concerns persist regarding its long-term psychological effects, particularly its potential role in the development of posttraumatic stress disorder (PTSD). Some studies...

DOI: 10.20408/jti.2025.0086 (opens in new tab) Full text (opens in new tab) Ketamine Critical care Neurobiology Post-traumatic stress disorders

Differential effects of ketamine enantiomers on EEG parameters including the gamma-delta shift phenomenon.

British Journal of Pharmacology June 1, 2026 Szabolcs Koncz, Dóra Pothorszki, Noémi Papp et al. 2 citations

Ketamine consists of two enantiomers, (R)-ketamine and (S)-ketamine, which exhibit distinct pharmacological properties. Currently, only the (S)-enantiomer has been approved for the treatment of major depressive disorder, whereas recent clinical studies have failed to demonstrate an antidepressant effect for (R)-ketamine. The quantitative electroencephalography (qEEG) gamma-enhancing effect of...

Adolescent ketamine exposure impairs spike timing-dependent plasticity and GABAergic transmission in pyramidal neurons of the mouse prefrontal cortex.

The Journal of Physiology June 1, 2026 Felipe Guiffa-Gómez, Sashá Van Buuren, Freddy Aguilar et al. 1 citation

The medial prefrontal cortex (mPFC) undergoes extensive GABAergic interneuron maturation during adolescence, a process that establishes excitatory-inhibitory balance and supports adult cognitive function. Disruptions during this critical developmental period contribute to neuropsychiatric disorders, yet the enduring consequences for adult synaptic plasticity remain poorly understood. Here we...

An Update on Somatic Treatments for Suicide Risk.

American Journal of Psychiatry June 1, 2026 Mina M Rizk, J John Mann 1 citation

Suicide is a major cause of death worldwide and a key public health challenge. Pharmacologic and neuromodulatory interventions are central to suicide prevention. This review summarizes evidence for these interventions with potential antisuicidal effects across major psychiatric disorders and, where possible, distinguishes their direct effects on suicide diathesis from those mediated by...

Synaptic Plasticity-Intrinsic Excitability and Antidepressant Discovery.

Biomedicines June 1, 2026 Masaru Tanaka

Major depressive disorder remains a leading cause of disability, and decades of monoamine-centered pharmacology have yielded delayed and often incomplete relief. Rapid-acting antidepressants reshaped the field by linking swift symptom improvement to glutamatergic plasticity, yet durable benefit depends on how newly reconfigured circuits are stabilized and tuned. This review synthesizes evidence...

(107) Chemsex: The Neuropharmacology of Pleasure and Risk

The Journal of Sexual Medicine June 1, 2026 M Almada, R Neto, A Pinto et al.

Abstract Introduction Emerging in the late 1990s within sexualized contexts, chemsex-the intentional use of psychoactive substances to enhance or prolong sexual activity-has evolved from a niche practice to a globally recognized public health concern, particularly among LGBTQ populations and men who have sex with men (MSM). Early accounts involved 3,4-methylenedioxymethamphetamine (MDMA) and...

DOI: 10.1093/jsxmed/qdag118.094 (opens in new tab) Full text (opens in new tab) Pleasure Public health Neuropharmacology Disease +9

Investigational drugs in PTSD.

Neuropsychopharmacology June 1, 2026 Ted Obi, Kerry J. Ressler

Post-traumatic stress disorder (PTSD) remains one of psychiatry's most challenging disorders, common, disabling, and biologically complex. Despite decades of research, only sertraline and paroxetine are FDA-approved, both with modest efficacy. Even first-line trauma-focused psychotherapies leave up to half of patients with persistent symptoms. However, advances in neurobiology are reframing...

Psychodynamic Perspectives on Psychedelic States and Treatment Contexts: A Conceptual and Clinical Introduction.

Psychodynamic psychiatry June 1, 2026 Nadav Liam Modlin, Zsofia Elek, Carolina Maggio et al.

Recent clinical trials have suggested the safety and efficacy of psychedelic therapy for treatment-resistant depression, posttraumatic stress disorder, addiction, and end-of-life distress. While neurobiological mechanisms such as 5-HT2A receptor activation, increased neural entropy, and default mode network modulation have been well-characterized, significantly less attention has been given to...

DOI: 10.1521/pdps.2026.54.2.338 (opens in new tab) Full text (opens in new tab) MDMA-Assisted Therapy Classical psychedelics Psychedelic treatment Psychodynamic psychiatry +1